Accessibility Menu
Takeda Pharmaceutical Stock Quote

Takeda Pharmaceutical (OTC: TKPHF)

$29.05
(6.3%)
+1.72
Price as of October 14, 2025, 3:10 p.m. ET

KEY DATA POINTS

Current Price
$29.05
Daily Change
(6.3%) +$1.72
Day's Range
$26.83 - $29.48
Previous Close
$29.05
Open
$29.48
Beta
0.08
Volume
1
Average Volume
69,523
Market Cap
45.4B
Market Cap / Employee
$29.05M
52wk Range
$24.25 - $32.13
Revenue
-
Gross Margin
0.53%
Dividend Yield
4.58%
EPS
$0.59
CAPs Rating
-
Industry
Pharmaceuticals

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Takeda Pharmaceutical Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
TKPHF+11.06%+9.26%+1.79%-18%
S&P+15.06%+95.03%+14.29%+591%

Takeda Pharmaceutical Company Info

Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following segments: Prescription Drug, Consumer Healthcare, and Other. The Prescription Drugs segment includes the manufacture and sale of pharmaceutical products. The Consumer Healthcare segment includes the manufacture and sale of OTC drugs and quasi-drugs. The Other segment includes manufacture and sale of reagents, clinical diagnostics, and chemical products. The company was founded by Takeda Chobei on June 12, 1781 and is headquartered in Osaka, Japan.

News & Analysis

Financial Health

General

Q2 2025YOY Change
Revenue$7.66B-1.2%
Gross Profit$4.09B-3.3%
Gross Margin53.35%-1.1%
Market Cap$44.61B5.9%
Market Cap / Employee$0.94M0.0%
Employees47.5K-3.7%
Net Income$860.12M40.6%
EBITDA$2.58B-2.5%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q2 2025YOY Change
Net Cash$2.42B-51.5%
Accounts Receivable$4.61B-1.9%
Inventory8.6K8.2%

Liabilities

Q2 2025YOY Change
Long Term Debt$28.63B-8.7%
Short Term Debt$2.57B-5.8%

Ratios

Q2 2025YOY Change
Return On Assets0.97%0.0%
Return On Invested Capital2.26%0.1%

Cash Flow

Q2 2025YOY Change
Free Cash Flow$1.08B65.0%
Operating Free Cash Flow$1.41B37.9%

Valuation

MetricQ3 2024Q4 2024Q1 2025Q2 2025YoY Change
Price to Earnings23.4830.7765.7450.3220.29%
Price to Book0.930.881.050.969.78%
Price to Sales1.531.441.551.6216.47%
Price to Tangible Book Value-3.13-3.02-3.80-3.3024.90%
Price to Free Cash Flow TTM21.6212.0115.4614.66-39.39%
Enterprise Value to EBITDA29.0431.9954.0030.0613.04%
Free Cash Flow Yield4.6%8.3%6.5%6.8%64.99%
Return on Equity4.0%2.9%1.5%2.0%-1.44%
Total Debt$35.31B$30.80B$34.03B$31.19B-8.45%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.